Evaluation of the optical purity of a new hydrophobic intraocular lens (IOL)

Session Details

Session Title: Pseudophakic IOLs: Toric, Multifocal, Accommodative

Session Date/Time: Monday 09/10/2017 | 14:30-16:00

Paper Time: 15:34

Venue: Room 4.1

First Author: : G.Auffarth GERMANY

Co Author(s): :    Q. Wang   H. Fang   P. Merz   S. Schickhardt           

Abstract Details

Purpose:

To generate and evaluate glistenings of three different hydrophobic and one hydrophilic acrylic intraocular lens model.

Setting:

The David J Apple International Laboratory for Ocular Pathology, University of Heidelberg, Germany

Methods:

Four IOL models (FineVision HP(POD F GF) [PhysIOL], FineVision(POD F) [PhysIOL], AcrySof IQ PanOptix [Alcon], Symfony [Abbott]) were analyzed. Glistenings were created in an experimental setup as aqueous-filled microvacuoles in five IOLs per model using an accelerated laboratory method. The IOLs were immersed in aqueous NaCl-solution (0.9%) at 45°C for 24 hours and then placed in a water bath with a temperature of 37°C for 2.5 hours to reduce the temperature. Images of the IOLs were taken with a camera attached to a microscope. The images were analyzed with an image analysis software (ImageJ) for the comparison of glistening formation.

Results:

The new FineVision HP (POD F GF) IOL convinced with a very small amount of glistenings (13,6 ± 15,0 MV/mm²). This amount is correlated to the Miyata Scale to value zero and the lens can be seen as glisteningsfree. For the hydrophilic FineVision (POD F) IOL (8,7 ± 12,7 MV/mm²) and the Symfony IOL (2,2 ± 1,3 MV/mm²) grade zero was detected too. The PanOptix generated a higher amount of glistenings (44,1 ± 19,3 MV/mm²) and is therefore classified as grade one on the Miyata Scale.

Conclusions:

The new FineVision HP (POD F GF) IOL developed only a small amount of glistenings and can be seen, like the hydrophilic FineVision (POD F) IOL and the Tecnis® Symfony, as a gisteningsfree lenses.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a competing company, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, research is funded, fully or partially, by a competing company, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives nonNONEmonetary benefits from a competing company., receives nonNONEmonetary benefits from a company producing, developing or supplying the product or procedure presented., receives consulting fees, retainer, or contract payments from a competing company